In Vitro and In Vivo Synergetic Radiotherapy with Gold Nanoparticles and Docetaxel for Pancreatic Cancer
Open Access
- 26 May 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 713
Abstract
This research underscores the potential of combining nanotechnology with conventional therapies in cancer treatment, particularly for challenging cases like pancreatic cancer. We aimed to enhance pancreatic cancer treatment by investigating the synergistic effects of gold nanoparticles (GNPs) and docetaxel (DTX) as potential radiosensitizers in radiotherapy (RT) both in vitro and in vivo, utilizing a MIA PaCa-2 monoculture spheroid model and NRG mice subcutaneously implanted with MIA PaCa-2 cells, respectively. Spheroids were treated with GNPs (7.5 μg/mL), DTX (100 nM), and 2 Gy of RT using a 6 MV linear accelerator. In parallel, mice received treatments of GNPs (2 mg/kg), DTX (6 mg/kg), and 5 Gy of RT (6 MV linear accelerator). In vitro results showed that though RT and DTX reduced spheroid size and increased DNA DSBs, the triple combination of DTX/RT/GNPs led to a significant 48% (p = 0.05) decrease in spheroid size and a 45% (p = 0.05) increase in DNA DSBs. In vivo results showed a 20% (p = 0.05) reduction in tumor growth 20 days post-treatment with (GNPs/RT/DTX) and an increase in mice median survival. The triple combination exhibited a synergistic effect, enhancing anticancer efficacy beyond individual treatments, and thus could be employed to improve radiotherapy and potentially reduce adverse effects.Keywords
Funding Information
- Kuwait Foundation for the Advancement of Sciences (CB21-63SP-01, R01CA257241, R01DE028105, R21CA252156, R01CA274415)
- Nanomedicines Innovation Network Strategic Initiative fund (NMIN-SI) (CB21-63SP-01, R01CA257241, R01DE028105, R21CA252156, R01CA274415)
- John R. Evans Leaders Fund (JELF) (CB21-63SP-01, R01CA257241, R01DE028105, R21CA252156, R01CA274415)
- British Columbia Knowledge Development Fund (BCKDF) (CB21-63SP-01, R01CA257241, R01DE028105, R21CA252156, R01CA274415)
- Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) (CB21-63SP-01, R01CA257241, R01DE028105, R21CA252156, R01CA274415)
- National Institutes of Health (NIH) of the United States of America (CB21-63SP-01, R01CA257241, R01DE028105, R21CA252156, R01CA274415)
- University of Victoria (CB21-63SP-01, R01CA257241, R01DE028105, R21CA252156, R01CA274415)
This publication has 54 references indexed in Scilit:
- Pancreatic cancerThe Lancet, 2011
- Targeted drug delivery to tumors: Myths, reality and possibilityJournal of Controlled Release, 2011
- Facile synthesis of concentrated gold nanoparticles with low size-distribution in water: temperature and pH controlsDiscover Nano, 2011
- Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studiesChemical Society Reviews, 2011
- Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinomaPhysics in Medicine & Biology, 2010
- Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?Journal of Nanoparticle Research, 2010
- Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinomaMolecular Cancer Therapeutics, 2008
- Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: a preliminary Monte Carlo studyPhysics in Medicine & Biology, 2005
- The use of gold nanoparticles to enhance radiotherapy in micePhysics in Medicine & Biology, 2004
- Pulse treatment of interphasic HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosisJournal of Cell Science, 1997